Protease inhibitors enhance levodopa effects in Parkinson's disease
Identifieur interne : 000A06 ( Istex/Corpus ); précédent : 000A05; suivant : 000A07Protease inhibitors enhance levodopa effects in Parkinson's disease
Auteurs : Dominique Caparros-Lefebvre ; Annie Lannuzel ; François Tiberghien ; Michel StrobelSource :
- Movement Disorders [ 0885-3185 ] ; 1999-05.
Url:
DOI: 10.1002/1531-8257(199905)14:3<535::AID-MDS1034>3.0.CO;2-S
Links to Exploration step
ISTEX:6BE0936FF1E50724857D55600AC1EC6AB4925B0DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Protease inhibitors enhance levodopa effects in Parkinson's disease</title><author><name sortKey="Caparros Efebvre, Dominique" sort="Caparros Efebvre, Dominique" uniqKey="Caparros Efebvre D" first="Dominique" last="Caparros-Lefebvre">Dominique Caparros-Lefebvre</name><affiliation><mods:affiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</mods:affiliation></affiliation></author><author><name sortKey="Lannuzel, Annie" sort="Lannuzel, Annie" uniqKey="Lannuzel A" first="Annie" last="Lannuzel">Annie Lannuzel</name><affiliation><mods:affiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</mods:affiliation></affiliation></author><author><name sortKey="Tiberghien, Francois" sort="Tiberghien, Francois" uniqKey="Tiberghien F" first="François" last="Tiberghien">François Tiberghien</name><affiliation><mods:affiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</mods:affiliation></affiliation></author><author><name sortKey="Strobel, Michel" sort="Strobel, Michel" uniqKey="Strobel M" first="Michel" last="Strobel">Michel Strobel</name><affiliation><mods:affiliation>Department of Infectious Diseases, CHU des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6BE0936FF1E50724857D55600AC1EC6AB4925B0D</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1002/1531-8257(199905)14:3<535::AID-MDS1034>3.0.CO;2-S</idno><idno type="url">https://api.istex.fr/document/6BE0936FF1E50724857D55600AC1EC6AB4925B0D/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000A06</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000A06</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Protease inhibitors enhance levodopa effects in Parkinson's disease</title><author><name sortKey="Caparros Efebvre, Dominique" sort="Caparros Efebvre, Dominique" uniqKey="Caparros Efebvre D" first="Dominique" last="Caparros-Lefebvre">Dominique Caparros-Lefebvre</name><affiliation><mods:affiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</mods:affiliation></affiliation></author><author><name sortKey="Lannuzel, Annie" sort="Lannuzel, Annie" uniqKey="Lannuzel A" first="Annie" last="Lannuzel">Annie Lannuzel</name><affiliation><mods:affiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</mods:affiliation></affiliation></author><author><name sortKey="Tiberghien, Francois" sort="Tiberghien, Francois" uniqKey="Tiberghien F" first="François" last="Tiberghien">François Tiberghien</name><affiliation><mods:affiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</mods:affiliation></affiliation></author><author><name sortKey="Strobel, Michel" sort="Strobel, Michel" uniqKey="Strobel M" first="Michel" last="Strobel">Michel Strobel</name><affiliation><mods:affiliation>Department of Infectious Diseases, CHU des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="1999-05">1999-05</date><biblScope unit="volume">14</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="535">535</biblScope><biblScope unit="page" to="536">536</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">6BE0936FF1E50724857D55600AC1EC6AB4925B0D</idno><idno type="DOI">10.1002/1531-8257(199905)14:3<535::AID-MDS1034>3.0.CO;2-S</idno><idno type="ArticleID">MDS1034</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Dominique Caparros‐Lefebvre MD, PhD</name><affiliations><json:string>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</json:string></affiliations></json:item><json:item><name>Annie Lannuzel MD, PhD</name><affiliations><json:string>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</json:string></affiliations></json:item><json:item><name>François Tiberghien MD</name><affiliations><json:string>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</json:string></affiliations></json:item><json:item><name>Michel Strobel MD</name><affiliations><json:string>Department of Infectious Diseases, CHU des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</json:string></affiliations></json:item></author><articleId><json:string>MDS1034</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>letter</json:string></originalGenre><qualityIndicators><score>5.012</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>0</abstractCharCount><pdfWordCount>5523</pdfWordCount><pdfCharCount>35038</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>1</abstractWordCount></qualityIndicators><title>Protease inhibitors enhance levodopa effects in Parkinson's disease</title><refBibs><json:item><author><json:item><name>T Lee</name></json:item><json:item><name>P Seeman</name></json:item><json:item><name>A Rajput</name></json:item><json:item><name>IJ Farley</name></json:item><json:item><name>O Horniekiewicz</name></json:item></author><host><volume>273</volume><pages><last>71</last><first>59</first></pages><author></author><title>Nature</title></host><title>Receptor basis for dopaminergic supersensitivity in Parkinson's disease</title></json:item><json:item><author><json:item><name>D Caparros‐Lefebvre</name></json:item></author><host><volume>73</volume><pages><last>944</last><first>938</first></pages><author></author><title>Sem Hôp Paris</title></host><title>Maladie de Parkinson: un traitement médical ou chirurgical adapté à la forme clinique</title></json:item><json:item><author><json:item><name>P Martinez‐Martin</name></json:item><json:item><name>CF O'Brien</name></json:item></author><host><volume>50</volume><pages><last>32</last><first>27</first></pages><issue>suppl 6</issue><author></author><title>Neurology</title></host><title>Extending levodopa action: COMT inhibition</title></json:item><json:item><author><json:item><name>VA Eagling</name></json:item><json:item><name>DJ Back</name></json:item><json:item><name>MG Barry</name></json:item></author><host><volume>44</volume><pages><last>194</last><first>190</first></pages><author></author><title>Br J Clin Pharmacol</title></host><title>Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir</title></json:item><json:item><author><json:item><name>MR Anari</name></json:item><json:item><name>S Khan</name></json:item><json:item><name>SD Jatoe</name></json:item><json:item><name>PJ O'Brien</name></json:item></author><host><volume>22</volume><pages><last>310</last><first>305</first></pages><author></author><title>Eur J Drug Metab</title></host><title>Cytochrome P450 dependent xenobiotic activation by physiological hydroperoxides in intact hepatocytes</title></json:item><json:item><author><json:item><name>LL Von Moltke</name></json:item><json:item><name>DJ Greenblatt</name></json:item><json:item><name>JM Grassi</name></json:item></author><host><volume>38</volume><pages><last>111</last><first>106</first></pages><author></author><title>J Clin Pharmacol</title></host><title>Protease inhibitors as inhibitors of human cytochrome P450: high risk associated with ritonavir</title></json:item></refBibs><genre><json:string>review-article</json:string></genre><host><volume>14</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>1</total><last>536</last><first>535</first></pages><issn><json:string>0885-3185</json:string></issn><issue>3</issue><subject><json:item><value>Letter to the Editor</value></json:item></subject><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><categories><wos><json:string>science</json:string><json:string>clinical neurology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>neurology & neurosurgery</json:string></scienceMetrix></categories><publicationDate>1999</publicationDate><copyrightDate>1999</copyrightDate><doi><json:string>10.1002/1531-8257(199905)14:3>535::AID-MDS1034>3.0.CO;2-S</json:string></doi><id>6BE0936FF1E50724857D55600AC1EC6AB4925B0D</id><score>0.16611259</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/6BE0936FF1E50724857D55600AC1EC6AB4925B0D/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/6BE0936FF1E50724857D55600AC1EC6AB4925B0D/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/6BE0936FF1E50724857D55600AC1EC6AB4925B0D/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Protease inhibitors enhance levodopa effects in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><availability><p>Copyright © 1999 Movement Disorder Society</p></availability><date>1999</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Protease inhibitors enhance levodopa effects in Parkinson's disease</title><author xml:id="author-1"><persName><forename type="first">Dominique</forename><surname>Caparros‐Lefebvre</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</affiliation></author><author xml:id="author-2"><persName><forename type="first">Annie</forename><surname>Lannuzel</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</affiliation></author><author xml:id="author-3"><persName><forename type="first">François</forename><surname>Tiberghien</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</affiliation></author><author xml:id="author-4"><persName><forename type="first">Michel</forename><surname>Strobel</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Infectious Diseases, CHU des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="1999-05"></date><biblScope unit="volume">14</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="535">535</biblScope><biblScope unit="page" to="536">536</biblScope></imprint></monogr><idno type="istex">6BE0936FF1E50724857D55600AC1EC6AB4925B0D</idno><idno type="DOI">10.1002/1531-8257(199905)14:3<535::AID-MDS1034>3.0.CO;2-S</idno><idno type="ArticleID">MDS1034</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1999</date></creation><langUsage><language ident="en">en</language></langUsage><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>Letter to the Editor</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1999-05">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/6BE0936FF1E50724857D55600AC1EC6AB4925B0D/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Inc.</publisherName><publisherLoc>New York</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="30"><doi origin="wiley" registered="yes">10.1002/1531-8257(199905)14:3<>1.0.CO;2-I</doi><numberingGroup><numbering type="journalVolume" number="14">14</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="1999-05">May 1999</coverDate></publicationMeta><publicationMeta level="unit" type="letter" position="34" status="forIssue"><doi origin="wiley" registered="yes">10.1002/1531-8257(199905)14:3<535::AID-MDS1034>3.0.CO;2-S</doi><idGroup><id type="unit" value="MDS1034"></id></idGroup><countGroup><count type="pageTotal" number="1"></count></countGroup><titleGroup><title type="articleCategory">Letter to the Editor</title><title type="tocHeading1">Letters to the Editor</title></titleGroup><copyright ownership="thirdParty">Copyright © 1999 Movement Disorder Society</copyright><eventGroup><event type="firstOnline" date="2001-01-23"></event><event type="publishedOnlineFinalForm" date="2001-01-23"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">535</numbering><numbering type="pageLast">536</numbering></numberingGroup><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS1034.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="6"></count><count type="wordTotal" number="1081"></count></countGroup><titleGroup><title type="main" xml:lang="en">Protease inhibitors enhance levodopa effects in Parkinson's disease</title><title type="short" xml:lang="en">Letters to the Editor</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Dominique</givenNames><familyName>Caparros‐Lefebvre</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Annie</givenNames><familyName>Lannuzel</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>François</givenNames><familyName>Tiberghien</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Michel</givenNames><familyName>Strobel</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>Department of Infectious Diseases, CHU des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</unparsedAffiliation></affiliation></affiliationGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Protease inhibitors enhance levodopa effects in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Letters to the Editor</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Protease inhibitors enhance levodopa effects in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Dominique</namePart><namePart type="family">Caparros‐Lefebvre</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Annie</namePart><namePart type="family">Lannuzel</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">François</namePart><namePart type="family">Tiberghien</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michel</namePart><namePart type="family">Strobel</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Infectious Diseases, CHU des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="letter"></genre><originInfo><publisher>John Wiley & Sons, Inc.</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">1999-05</dateIssued><copyrightDate encoding="w3cdtf">1999</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">6</extent><extent unit="words">1081</extent></physicalDescription><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>Letter to the Editor</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>535</start><end>536</end><total>1</total></extent></part></relatedItem><identifier type="istex">6BE0936FF1E50724857D55600AC1EC6AB4925B0D</identifier><identifier type="DOI">10.1002/1531-8257(199905)14:3<535::AID-MDS1034>3.0.CO;2-S</identifier><identifier type="ArticleID">MDS1034</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1999 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>John Wiley & Sons, Inc.</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A06 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000A06 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:6BE0936FF1E50724857D55600AC1EC6AB4925B0D
|texte= Protease inhibitors enhance levodopa effects in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.29. |  |